Although in previous clinical trials, the therapeutic effects of most lysosome inhibitors were disappointing against various cancers such as pancreatic cancer, colon cancer, glioma, and breast cancer63–67, the potent effect of CQ in blocking LAPTM5 and restoring BMPR1A levels makes it a promising therapeutic agent for patients with lung metastasis. Here, BMPR1A is linked to familial pancreatic carcinoma.